PYC Therapeutics Limited (AU:PYC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PYC Therapeutics (ASX:PYC) is advancing its VP-001 drug candidate, aimed at treating Retinitis Pigmentosa type 11, with promising results from its Phase 1/2 clinical trials showing improved vision in patients. The company is gearing up for discussions with the FDA to initiate a registrational trial in 2025, signaling a significant step towards addressing a market valued at over $1 billion annually. This development is part of PYC’s broader strategy to deliver first-in-class RNA therapies for genetic diseases.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.